NextCell Pharma AB
Mathias Svahn is an experienced professional in the biotechnology and medical sectors, currently serving as Chairman and CEO of Cellaviva, as well as CEO of NextCell Pharma AB, and a member of the supervisory boards for both Cellaviva and FamiCordTx. Svahn's previous roles include Senior Researcher at Karolinska Institutet and Country Medical Manager at Roche, focusing on oncology and pipeline substances. Svahn holds multiple doctoral degrees in Molecular Cell Biology and Gene Therapy from Karolinska Institutet, along with a Master of Science in Molecular Biotechnology from Uppsala University and a Master's in Economics and Entrepreneurship from the Stockholm School of Economics. With extensive experience in clinical studies, project management, and research, Svahn has contributed significantly to efforts in stroke care and cellular therapies.
This person is not in any teams
NextCell Pharma AB
NextCell Pharma is an innovative Biotech growing out of the need for Advanced Therapy Medicinal Products for Autoimmune Disease and Transplantation. Cellaviva, the first Swedish family saving stem cell bank, with its expertise in umbilical cord stem cells and Diamyd Medical with its interests and investments within autoimmune diseases made a natural partnership for creating NextCell Pharma. Clinical trials testing NextCell Pharma’s first product, ProTrans,has started in Novermber 2018. #nextcellpharma #cellaviva